Allianz Asset Management GmbH - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$637,321
-79.6%
14,041
-74.8%
0.00%
-83.3%
Q2 2023$3,130,535
+28.1%
55,763
+3.2%
0.01%
+50.0%
Q1 2023$2,444,727
+19.0%
54,051
+6.9%
0.00%0.0%
Q4 2022$2,054,939
-37.5%
50,552
+0.4%
0.00%
-42.9%
Q3 2022$3,290,000
+98.6%
50,343
+84.6%
0.01%
+250.0%
Q2 2022$1,657,000
-3.2%
27,2720.0%0.00%
+100.0%
Q1 2022$1,711,000
-47.8%
27,272
-36.8%
0.00%
-50.0%
Q4 2021$3,277,000
-30.4%
43,137
+2.6%
0.00%
-50.0%
Q3 2021$4,707,000
-56.1%
42,062
-36.5%
0.00%
-55.6%
Q2 2021$10,725,000
+240.9%
66,248
+156.5%
0.01%
+200.0%
Q1 2021$3,146,000
-6.9%
25,827
+17.1%
0.00%0.0%
Q4 2020$3,379,000
-3.0%
22,064
-73.1%
0.00%
-40.0%
Q1 2020$3,483,000
+69.2%
82,123
+142.9%
0.01%
+150.0%
Q4 2019$2,059,000
+25.9%
33,807
-14.8%
0.00%0.0%
Q3 2019$1,636,000
-42.4%
39,676
-34.2%
0.00%
-33.3%
Q2 2019$2,838,000
-0.1%
60,270
-24.2%
0.00%0.0%
Q1 2019$2,840,000
+62.1%
79,516
+27.5%
0.00%
+50.0%
Q4 2018$1,752,000
-34.0%
62,352
+4.2%
0.00%0.0%
Q3 2018$2,653,000
-64.0%
59,825
-52.3%
0.00%
-71.4%
Q2 2018$7,372,000
-30.7%
125,457
-46.1%
0.01%
-30.0%
Q1 2018$10,639,000
+95.2%
232,744
+0.3%
0.01%
+150.0%
Q4 2017$5,449,000
+128.6%
232,060
+74.0%
0.00%
+100.0%
Q3 2017$2,384,000133,3700.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders